Tempest Therapeutics Appoints Troy M. Wagner as VP of Quality
![Tempest Therapeutics Appoints Troy M. Wagner as VP of Quality](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
Tempest Therapeutics Announces New VP of Quality Assurance
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class targeted and immune-mediated therapeutics to fight cancer, today announced the appointment of Troy M. Wagner as Vice President of Quality Assurance.
Experience and Contributions
“Troy brings a wealth of experience in late-stage product development, including managing quality systems across a range of global clinical studies and assisting with global regulatory filings. We look forward to her contributions as we move towards Phase 3 development of amezalpat to treat hepatocellular carcinoma and are thrilled to have her join the Tempest leadership team,” said Stephen Brady, president and chief executive officer of Tempest.
Statement from Troy M. Wagner
Ms. Wagner added, “This is a great time to join Tempest. The company’s lead oncology candidate, amezalpat, has yielded exciting clinical results in liver cancer, showing its potential to transform the treatment landscape for a historically hard to treat cancer. I look forward to working with the team with the goal to bring this promising potential therapy to patients.”
Professional Background of Troy M. Wagner
Ms. Wagner joined Tempest as vice president of quality assurance, bringing over 30 years of experience in quality and clinical compliance. She has managed compliance, quality assurance, and quality control in various pharmaceutical and device manufacturing sites, as well as provided regulatory agency liaison support and oversaw the implementation of corporate quality standards.
Prior to Tempest, she was the Vice President of Quality Assurance at Tricida, Inc., where she led all quality assurance functions for manufacturing, testing, holding, and distribution activities. Before Tricida, Ms. Wagner served as Head of Global Corporate Quality & Compliance at Jubilant Life Sciences Ltd. and held key positions at several other companies, including Alcon and Nektar Therapeutics.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs span early research to later-stage investigations in randomized global studies targeting first-line cancer patients.
Investor Contacts
Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Frequently Asked Questions
Who is the new Vice President of Quality Assurance at Tempest?
Troy M. Wagner has been appointed as the new Vice President of Quality Assurance at Tempest Therapeutics.
What experience does Troy M. Wagner bring to Tempest?
Troy M. Wagner brings over 30 years of experience in quality and clinical compliance from various roles in the pharmaceutical industry.
What is the focus of Tempest Therapeutics?
Tempest Therapeutics focuses on developing targeted and immune-mediated therapeutics to fight cancer, with a diverse portfolio of product candidates.
What is the significance of amezalpat for Tempest?
Amezalpat is Tempest's lead oncology candidate, which has shown promising clinical results for treating liver cancer.
How can investors contact Tempest Therapeutics?
Investors can contact Sylvia Wheeler or Aljanae Reynolds at Wheelhouse Life Science Advisors via the provided email addresses.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/